Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViroGates ASFRA:EP2 24 Earnings Yield (Joel Greenblatt) % is -12.97% as of Mar. 2026. GuruFocus rates FRA:EP2 with a GF Score™ of 24/100 and a GF Value™ of €0.87 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 849 Medical Devices & Instruments companies, ViroGates AS ranks worse than 76.56% on this metric.
ViroGates AS's Enterprise Value for the quarter that ended in Mar. 2026 was €10.76 Mil.
ViroGates AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.41 Mil. ViroGates AS's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -12.97%.
The historical rank and industry rank for ViroGates AS's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:EP2'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -44.81 Med: -13.86 Max: -2.55
Current: -12.69
During the past 10 years, the highest Earnings Yield (Joel Greenblatt) of ViroGates AS was -2.55%. The lowest was -44.81%. And the median was -13.86%.
FRA:EP2's Earnings Yield (Joel Greenblatt) % is ranked worse than 76.56% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 0.86
vs FRA:EP2: -12.69
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. ViroGates AS's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
ViroGates AS (FRA:EP2) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
ViroGates AS Earnings Yield (Joel Greenblatt) % Related Terms
ViroGates AS Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for ViroGates AS's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ViroGates AS Earnings Yield (Joel Greenblatt) % Chart
For the Medical Devices subindustry, ViroGates AS's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ViroGates AS Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ViroGates AS's Earnings Yield (Joel Greenblatt) % falls into.
ViroGates AS Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
ViroGates ASs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
ViroGates AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.41 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -12.97% mean?
ViroGates AS (FRA:EP2) has a Earnings Yield (Joel Greenblatt) % of -12.97% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #650 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 76.6%.
Is ViroGates AS's Earnings Yield (Joel Greenblatt) % too high?
ViroGates AS's current Earnings Yield (Joel Greenblatt) % is -12.97%. Based on the distribution chart, ViroGates AS ranks #650 out of 849 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ViroGates AS has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Earnings Yield (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #650 out of 849 companies for Earnings Yield (Joel Greenblatt) %. This places ViroGates AS in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.86, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current Earnings Yield (Joel Greenblatt) % is -12.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (FRA:EP2) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.87, compared to a current price of €1.45 — trading 66.7% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -12.97%. ViroGates AS's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current Earnings Yield (Joel Greenblatt) % is -12.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ViroGates AS (FRA:EP2) Overvalued in 2026?
Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued.
The current stock price of €1.45 is trading 66.7% above its estimated GF Value™ of €0.87.
GuruFocus considers ViroGates AS to be Significantly Overvalued.
Key valuation signals for FRA:EP2:
Earnings Yield (Joel Greenblatt) %: -12.97%
GF Value™: €0.87 vs. price of €1.45 (66.7% above fair value)
No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
24GF Score
Get the complete analysis for FRA:EP2
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EP2 has been successfully added to your 
